Axsome Therapeutics (AXSM) Net Equity Issued and Repurchased (2017 - 2026)

Axsome Therapeutics has reported Net Equity Issued and Repurchased for 10 years, with the latest figure at $6.3 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 67.72% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.6 million (up 11.04% YoY) and the FY2025 annual result came in at $67.9 million, up 66.5% from the prior year.
• Net Equity Issued and Repurchased grew to $6.3 million in Q1 2026 per AXSM's latest filing, from $5.7 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $211.3 million in Q2 2023 and troughed at $5.7 million in Q4 2025.
• A 5-year average of $49.4 million and a median of $25.3 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2022 and 2023: Net Equity Issued and Repurchased soared 2868.62% in 2022, then sank 81.27% in 2023.
• Over 5 years, Net Equity Issued and Repurchased stood at $180.2 million in 2022, then tumbled by 81.27% to $33.8 million in 2023, then tumbled by 51.35% to $16.4 million in 2024, then slumped by 65.44% to $5.7 million in 2025, then grew by 11.77% to $6.3 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $6.3 million, $5.7 million, and $9.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.